Xilio Therapeutics Inc (XLO)
1.29
+0.21
(+19.44%)
USD |
NASDAQ |
May 20, 16:00
1.17
-0.12
(-9.30%)
After-Hours: 20:00
Xilio Therapeutics Cash from Financing (TTM): -3.908M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -3.908M |
December 31, 2023 | -6.55M |
September 30, 2023 | -4.937M |
June 30, 2023 | -2.723M |
March 31, 2023 | -1.752M |
Date | Value |
---|---|
December 31, 2022 | -0.069M |
September 30, 2022 | 115.78M |
June 30, 2022 | 116.10M |
March 31, 2022 | 115.77M |
December 31, 2021 | 260.67M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-6.55M
Minimum
Dec 2023
260.67M
Maximum
Dec 2021
58.84M
Average
-0.9105M
Median
Cash from Financing (TTM) Benchmarks
Gilead Sciences Inc | -5.08B |
FibroGen Inc | 91.10M |
Avalo Therapeutics Inc | 119.91M |
IGM Biosciences Inc | 115.14M |
AEON Biopharma Inc | -- |